Loading
HKSEHealthcareMedical - Diagnostics & Research
Latest quote
HK$188.8
−HK$2.20 · -1.15%
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
Latest quote
HK$188.8
−HK$2.20 · -1.15%
Regular session · HKT · Market data may be delayed.
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
Day range
Current HK$188.8
52-week range
Current HK$188.8
Regular session · HKT · Market data may be delayed.
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
Day range
Current HK$188.8
52-week range
Current HK$188.8
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 45.46B CNY | 39.24B CNY | 40.34B CNY | 39.35B CNY | 22.9B CNY |
| Cost of goods sold | 23.8B CNY | 22.96B CNY | 23.77B CNY | 24.68B CNY | 14.59B CNY |
| Gross profit | 21.65B CNY | 16.28B CNY | 16.57B CNY | 14.68B CNY | 8.31B CNY |
| Research and development | 1.12B CNY | 1.24B CNY | 1.44B CNY | 1.61B CNY | 942.24M CNY |
| Selling, general, and administrative | 930.63M CNY | 969.71M CNY | 1.09B CNY | 1.66B CNY | 1.47B CNY |
| Operating expenses | 4.65B CNY | 4.7B CNY | 4.74B CNY | 4.93B CNY | 3.65B CNY |
| Interest income | 938.02M CNY | 626.76M CNY | 444.47M CNY | 221.93M CNY | 191.69M CNY |
| Interest expense | 306.49M CNY | 216.03M CNY | 74.82M CNY | 185.87M CNY | 128.33M CNY |
| Depreciation and amortization | 3.47B CNY | 2.78B CNY | 2.28B CNY | 1.69B CNY | 1.29B CNY |
| Operating income | 17B CNY | 11.58B CNY | 11.87B CNY | 10.65B CNY | 6.04B CNY |
| Net income | 19.15B CNY | 9.45B CNY | 9.61B CNY | 8.81B CNY | 5.1B CNY |
Company facts updated Sep 13, 2026.
Cash distributions grouped by calendar year; partial years are marked.
HK$1.4426
2025 complete year+291.1% since 2021
2026 partial: HK$2.3918
HK$0.3688
2,021
HK$0.6163
2,022
HK$0.9889
2,023
HK$1.087
2,024
HK$1.4426
2,025
HK$2.3918
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 18, 2026 | HK$0.589Quarterly | Aug 19, 2026 | Sep 4, 2026 |
Dividend | May 13, 2026 | HK$1.8028Irregular | May 15, 2026 | May 29, 2026 |
Dividend | Sep 8, 2025 | HK$0.3846Semi-Annual | Sep 9, 2025 | Sep 26, 2025 |
Dividend | May 15, 2025 | HK$1.058Semi-Annual | May 16, 2025 | Jun 5, 2025 |
Dividend | Jun 17, 2024 | HK$1.087Annual | Jun 18, 2024 | Jul 5, 2024 |
Dividend | Jun 5, 2023 | HK$0.9889Annual | Jun 6, 2023 | Jun 27, 2023 |
Ex-dividend Aug 18, 2026
HK$0.589
Quarterly
Record Aug 19, 2026 · Payment Sep 4, 2026
Ex-dividend May 13, 2026
HK$1.8028
Irregular
Record May 15, 2026 · Payment May 29, 2026
Ex-dividend Sep 8, 2025
HK$0.3846
Semi-Annual
Record Sep 9, 2025 · Payment Sep 26, 2025
Ex-dividend May 15, 2025
HK$1.058
Semi-Annual
Record May 16, 2025 · Payment Jun 5, 2025
Ex-dividend Jun 17, 2024
HK$1.087
Annual
Record Jun 18, 2024 · Payment Jul 5, 2024
Ex-dividend Jun 5, 2023
HK$0.9889
Annual
Record Jun 6, 2023 · Payment Jun 27, 2023
1276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
HK$43.76
-0.45%
6160.HK
BeOne Medicines AG
HK$206.2
-0.39%
3692.HK
Hansoh Pharmaceutical Group Company Limited
HK$32.72
-1.86%
2269.HK
WuXi Biologics (Cayman) Inc.
HK$47.00
-1.05%
1801.HK
Innovent Biologics, Inc.
HK$93.55
-0.85%
6618.HK
JD Health International Inc.
HK$34.74
+0.29%
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS133.74M0.02%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Emerging Markets ETFVWO126.95M0.07%162.3B USD0.06%$60.35+0.69%
iShares Core MSCI Emerging Markets ETFIEMG111.4M0.07%162.15B USD0.09%$82.57+1.21%
iShares Core MSCI China ETF2801.HK47.08M0.39%12.21B HKD0.20%HK$24.20+1.51%
iShares China Large-Cap ETFFXI38.27M0.92%4.12B USD0.73%$34.49+0.41%
iShares Core MSCI Asia ex Japan ETF3010.HK31.65M0.08%37.02B HKD0.28%HK$90.32-1.12%
Capital Group International Focus Equity ETFCGXU30.88M0.45%6.91B USD0.54%$35.32+1.29%
iShares Core MSCI Asia ex Japan ETF83010.HK27.05M0.08%31.64B CNY0.28%CN¥77.04-1.76%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGiShares Core MSCI China ETF2801.HKiShares China Large-Cap ETFFXIiShares Core MSCI Asia ex Japan ETF3010.HKCapital Group International Focus Equity ETFCGXUiShares Core MSCI Asia ex Japan ETF83010.HKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.